Mitsubishi Tanabe adds to confidence on vadadustat

11 November 2019

Mitsubishi Tanabe Pharma (TYO: 4508) has presented new results on vadadustat in renal anemia, having filed for approval in this setting in Japan in July with its convenient once-a-day oral administration therapy.

The Japanese company has presented the results at the American Society of Nephrology, Kidney Week 2019, which are from a Phase III trial in anemia in non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients in Japan.

This study showed non-inferiority of vadadustat in mean hemoglobin (Hb) level at week 20 and week 24 to that of darbepoetin alfa, a drug that was originally marketed by Amgen (Nasdaq: AMGN) under the brand name Aranesp.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK